Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30541576 | 1.00 | GPR119 (0.42) | GPR119CYP2D6KCNJ1PTGS2MAP4K1 | |
| SCHEMBL25364996 | 0.96 | GPR119 (0.42) | GPR119CYP2D6KCNJ1PTGS2CA12 | |
| SCHEMBL30541585 | 0.96 | GPR119 (0.42) | GPR119CYP2D6KCNJ1PTGS2CA12 | |
| SCHEMBL25364132 | 0.90 | GPR119 (0.44) | GPR119CYP2D6 | |
| SCHEMBL30541639 | 0.89 | GPR119 (0.39) | GPR119PTGS2MAP4K1CA12CA1 | |
| SCHEMBL25366291 | 0.89 | GPR119 (0.39) | GPR119PTGS2MAP4K1CA12CA1 | |
| SCHEMBL30541624 | 0.88 | GPR119 (0.37) | GPR119PTGS2MAP4K1CA12CA1 | |
| SCHEMBL25366102 | 0.88 | GPR119 (0.37) | GPR119PTGS2MAP4K1CA12CA1 | |
| SCHEMBL25366514 | 0.86 | CYP2D6 (0.39) | GPR119CYP2D6KCNJ1PTGS2USP2 | |
| SCHEMBL30541651 | 0.86 | CYP2D6 (0.39) | GPR119CYP2D6KCNJ1PTGS2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | claimed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | claimed |
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | GPR119 79/4885CYP2D6 4333/4885KCNJ1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.